Bard prevails again in stent graft patent war with W.L. Gore

October 18, 2013 by Brad Perriello

A federal judge upholds C.R. Bard's patent infringement win over W.L. Gore & Assoc. in their decades-long war over stent graft technology, setting Bard up to collect some $800 million in damages, royalties and legal fees.

Bard prevails again in stent graft patent war with W.L. Gore

C.R. Bard (NYSE:BCR) won another round in its decades-long patent infringement war with W.L. Gore & Assoc. over stent graft technology after a federal judge found yesterday that Gore willfully infringed the patent.

An appeals court last year tasked Judge Mary Murguia of the U.S. District Court for Arizona with reviewing her prior finding of willfulness. Yesterday Murguia upheld that ruling, finding Gore's infringement willful and declining to revisit her decision on enhanced damages and legal fees and denying Gore's bid for a new trial, according to court documents.

"[I]t is clear to this court, just as it was to the jury, that defendant, as a 'reasonable litigant,' could not have 'realistically expected' its defenses to succeed. Defendant's incautious and arguably reckless defenses were not objectively reasonable. It is unnecessary for the court to reconsider its ruling on enhanced damages and attorney's fees," according to the documents.

Sign up to get our free newsletters delivered straight to your inbox

Murguia also granted Bard's motion to execute on the enhanced damages and legal fees, according to the court records. The decision sets Bard up to collect roughly $800 million in damages, legal costs and royalties, according to the documents.

Gore had alleged that 1 of its engineers, Peter Cooper, invented a key claim in the patent in the early 1970s, according to a petition for a writ of certiorari filed with the high court.